DNMT3A and acute myeloid leukemia: Myelomonocytoid and monocytoid / monoblastic AML (FAB M4 and M5) accounts for approximately 25% of total AML cases [44]; these cases have a distinct clinical profile with frequent extramedullary manifestations and leucocytosis along with emerging associations with abnormalities in epigenetic regulation in the form of DNMT3A mutations [45, 46].